Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line

Journal of Orthopaedic Science

Volumn 8, Issue 4, 2003, Pages 554-559

  Nabeta, Yuki ^a   Kawaguchi, Satoshi ^a   Sahara, Hiroeki ^a   Ikeda, Hideyuki ^a   Hirohashi, Yoshihiko ^a   Goroku, Takahiro ^a   Sato, Yuriko ^a   Tsukahara, Tomohide ^a   Torigoe, Toshihiko ^a   Wada, Takuro ^a   Kaya, Mitsunori ^a   Hiraga, Hiroaki ^b   Isu, Kazuo ^b   Yamawaki, Shinya ^b   Ishii, Seiichi ^a   Yamashita, Toshihiko ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO CANCER CENTER   (Japan)

Author keywords

CTL; Cytotoxic T lymphocytes; Osteosarcoma; SEREX; Tumor antigen

Indexed keywords

COLLAGEN TYPE 1; HLA C ANTIGEN; HLA CLASS I MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MYOSIN LIGHT CHAIN; OSTEOCALCIN; UNCLASSIFIED DRUG;

ADULT; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; RETINOBLASTOMA; SEREX METHOD; SEROLOGY; SERUM; T LYMPHOCYTE; WILD TYPE;

EID: 0043014804     PISSN: 09492658     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00776-003-0663-5     Document Type: Article

References (19)

1. Chicz RM, Urban RG, Gorga JC, et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27-47.
2. Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 1996;14:467-72.
3. Ichino Y, Ishikawa T. Cytolysis of autologous fresh osteosarcoma cells by human cytotoxic T lymphocytes propagated with T cell growth factor. Gann 1983;74:584-94.
4. Jager E, Jager D, Karbach J, et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000;191:625-30.
5. Jager D, Jager E, Knuth A. Vaccination for malignant melanoma: recent developments. Oncology 2001;60:1-7.
6. Katsuki T, Hinuma Y. Characteristics of cell lines derived from human leukocytes transformed by different strains of Epstein-Barr virus. Int J Cancer 1975;15:203-10.
7. Kawai K, Matsuhisa T, Sakurai M, et al. Establishment and characterization of a second primary osteosarcoma cell line (OSrb/N-M) from a patient cured of bilateral retinoblastoma. Cancer Lett 1999;135:37-46.
8. Latif N, Baker CS, Dunn MJ, et al. Frequency and specificity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and Western blotting. J Am Coll Cardiol 1993;22:1378-84.
9. Maeda A, Ohguro H, Nabeta Y, et al. Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer-associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome. Eur J Immunol 2001;31:563-72.
10. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
11. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-94.
12. Park YB, Park MJ, Kimura K, et al. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines, Cancer Genet Cytogenet 2002;133:105-11.
13. Rickard DJ, Kassem M, Hefferan TE, et al. Isolation and characterization of osteoblast precursor cells from human bone marrow. J Bone Miner Res 1996;11:312-24.
14. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
15. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-3.
16. Sato T, Sato N, Takahashi S, et al. Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells. Cancer Res 1986;46:4384-9.
17. Sato Y, Nabeta Y, Tsukahara T, et al. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol 2002;169:1611-8.
18. Wong IH, Chan AT, Johnson PJ. Quantitative analysis of circulating tumor cells in peripheral blood of osteosarcoma patients using osteoblast-specific messenger RNA markers: a pilot study. Clin Cancer Res 2000;6:2183-8.
19. Zorn E, Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 1999;29:592-601.